Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of the company’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the sale, the director owned 384,682 shares in the company, valued at $73,281,921. This trade represents a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Stock Performance

JAZZ stock remained flat at $186.95 during mid-day trading on Friday. The company’s stock had a trading volume of 695,901 shares, compared to its average volume of 824,700. The company has a market capitalization of $11.51 billion, a P/E ratio of -31.31, a price-to-earnings-growth ratio of 0.34 and a beta of 0.23. Jazz Pharmaceuticals PLC has a 1-year low of $95.49 and a 1-year high of $198.00. The business’s 50 day moving average price is $177.03 and its 200 day moving average price is $161.48. The company has a debt-to-equity ratio of 1.00, a quick ratio of 1.67 and a current ratio of 1.86.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 EPS for the quarter, beating the consensus estimate of $6.49 by $0.15. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The company had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. During the same period last year, the business posted $6.51 EPS. The firm’s revenue for the quarter was up 8.1% compared to the same quarter last year. As a group, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on JAZZ. Needham & Company LLC upped their price objective on Jazz Pharmaceuticals from $210.00 to $235.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Wells Fargo & Company increased their target price on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Piper Sandler boosted their price objective on Jazz Pharmaceuticals from $219.00 to $232.00 and gave the stock an “overweight” rating in a report on Thursday, March 19th. Barclays restated an “overweight” rating and set a $224.00 price target on shares of Jazz Pharmaceuticals in a research report on Monday, March 9th. Finally, Morgan Stanley upped their price objective on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $215.38.

Institutional Trading of Jazz Pharmaceuticals

Several institutional investors have recently bought and sold shares of JAZZ. Farther Finance Advisors LLC increased its holdings in shares of Jazz Pharmaceuticals by 754.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 265 shares of the specialty pharmaceutical company’s stock worth $35,000 after purchasing an additional 234 shares in the last quarter. Hilltop National Bank bought a new position in shares of Jazz Pharmaceuticals during the 4th quarter valued at approximately $36,000. LRI Investments LLC bought a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $38,000. Danske Bank A S bought a new stake in Jazz Pharmaceuticals during the third quarter valued at about $40,000. Finally, Quent Capital LLC purchased a new position in Jazz Pharmaceuticals in the 3rd quarter worth approximately $44,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.